Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VW0I
|
|||
| Former ID |
DNC000499
|
|||
| Drug Name |
Cyclopentenylcytosine
|
|||
| Synonyms |
cyclopentenyl cytosine; 90597-22-1; NSC-375575; CPE-C; UNII-69MO0NDN8K; NSC 375575; NSC375575; BRN 4258358; 69MO0NDN8K; CHEMBL63647; 1-((1R,2S,3R)-4-Hydroxymethyl-2,3-dihydroxy-4-cyclopenten-1-yl)cytosine; 4-amino-1-[(1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one; 4-amino-1-[(1r,4r,5s)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2(1h)-one; CPE-cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H13N3O4
|
|||
| Canonical SMILES |
C1=CN(C(=O)N=C1N)C2C=C(C(C2O)O)CO
|
|||
| InChI |
1S/C10H13N3O4/c11-7-1-2-13(10(17)12-7)6-3-5(4-14)8(15)9(6)16/h1-3,6,8-9,14-16H,4H2,(H2,11,12,17)/t6-,8-,9+/m1/s1
|
|||
| InChIKey |
DUJGMZAICVPCBJ-VDAHYXPESA-N
|
|||
| CAS Number |
CAS 90597-22-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CTP synthase (CTPS1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Pyrimidine metabolism | |||
| Metabolic pathways | ||||
| Panther Pathway | De novo pyrimidine ribonucleotides biosythesis | |||
| Pathwhiz Pathway | Pyrimidine Metabolism | |||
| WikiPathways | Metabolism of nucleotides | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol. 1995;36(6):513-23. | |||
| REF 2 | Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.